Core Insights - Levi Strauss & Co. (LEVI) reported strong second-quarter fiscal 2025 results, with earnings per share (EPS) of 22 cents, surpassing the Zacks Consensus Estimate of 14 cents, and a year-over-year increase of 37.5% from 16 cents [3][10] - Net revenues reached $1.45 billion, exceeding the Zacks Consensus Estimate of $1.37 billion, and reflecting a 6% year-over-year increase on a reported basis and 9% on an organic basis [3][10] - The company is transitioning into a denim lifestyle brand and a leading direct-to-consumer (DTC) retailer, supported by positive comparable sales growth and robust e-commerce performance [1][2] Financial Performance - DTC net revenues increased by 11% on a reported basis and 10% on an organic basis, totaling $716.1 million, with growth driven by a 9% rise in the U.S., 9% in Europe, and 10% in Asia [5][6] - Wholesale net revenues rose 3% on a reported basis to $729.9 million, with a 7% increase on an organic basis [6] - Gross profit increased by 8.8% year over year to $905.8 million, with gross margin expanding by 140 basis points to 62.6% [11] Market Performance - LEVI's shares rose over 5% in after-hours trading following the earnings report, with a 31.9% increase in share price over the past three months compared to the industry growth of 25.9% [4] - The company reported its 13th consecutive quarter of positive global comparable sales [10] Regional Insights - In the Americas, revenues increased by 5% on a reported basis and 9% on an organic basis, with double-digit growth in both DTC and wholesale channels [7] - European revenues jumped 14% on a reported basis and 15% on an organic basis [7] - In Asia, revenues remained flat due to strategic adjustments, but DTC showed double-digit growth in markets like Japan and Turkey [8] Future Outlook - For Q3, LEVI projects net revenue growth of 1-2%, an increase from the previous forecast of (1%) to (2%), with organic net revenue growth expected to be 4.5-5.5% [15] - The company anticipates gross margin to increase by 80 basis points and adjusted EBIT margin to be in the range of 11.4-11.6% [16] - Adjusted EPS is projected to be between $1.25 and $1.30, up from the previous estimate of $1.20 to $1.25 [16]

Bank of America Securities (BofA) analyst Jessica Reif Ehrlich maintained a Buy rating on Walt Disney DIS with a price forecast of $140 on Friday, signaling confidence in the entertainment giant’s ongoing recovery, particularly within its crucial Experiences segment.Reif Ehrlich projects a sequential improvement in the Experiences segment’s operating income (OI) for Disney’s fiscal third quarter, with an anticipated acceleration in the fiscal fourth quarter, supported by easier year-over-year comparisons.Th ...

Core Viewpoint - Amer Sports has experienced a significant stock price increase of approximately 187% since its public offering in February 2024, positioning it as a leading name in the consumer discretionary sector [1][2] Financial Performance - The company reported a strong Q1 earnings performance, with sales growth exceeding 23%, surpassing analyst expectations of just under 17% [3] - Adjusted diluted earnings per share (EPS) more than doubled from $0.11 to $0.27, significantly exceeding forecasts [4] - Amer Sports raised its full-year EPS guidance midpoint by over 4% and increased its revenue growth guidance from 14% to 16%, both ahead of analyst expectations [4] Brand and Market Position - Amer Sports' success is largely attributed to its key brand, Arc'teryx, known for high-end outdoor clothing, particularly lightweight waterproof jackets priced between $400 and $900 [6] - The technical apparel segment, which includes Arc'teryx, saw the fastest revenue growth at 28%, contributing 45% to total revenue [7] - Sales in Greater China grew by 43%, accounting for around 25% of total revenue, while the U.S. market contributed 26% with a 12% growth rate [7][8] Direct-to-Consumer Strategy - The company's direct-to-consumer (DTC) sales grew by 39%, significantly outpacing the 12% growth in its wholesale channel, indicating a positive trend for higher margins [8] Segment Performance - The Outdoor Performance segment, which includes Salomon footwear and apparel, saw its growth rate nearly double to 25%, making up 34% of total revenue [9] - Salomon generated $1 billion in revenue in 2024, capturing less than 1% of the global $180 billion sneaker market, with plans for further product launches [10] Valuation and Analyst Ratings - Analysts have raised their price targets for Amer Sports, with an average target just under $41, indicating a potential upside of 6% from recent closing prices [11] - The stock's price-to-earnings ratio stands at nearly 49x, significantly above the industry average of 29x, reflecting its strong earnings and sales growth profile [12] Future Outlook - The company is viewed as having high growth potential, particularly in the footwear segment, but expectations for continued outperformance will need to be managed [13]

24 May 2025 | 1:54AM HKT Miniso (MNSO) Buy Earnings review: A year of transition; SSSG sequentially improved, but margin still dragged by DTC; Buy | MNSO | 12m Price Target: $23.40 | Price: $22.19 | Upside: 5.5% | | --- | --- | --- | --- | | 9896.HK | 12m Price Target: HK$46.00 | Price: HK$42.25 | Upside: 8.9% | Miniso reported 1Q25 with 19% yoy revenue growth which was slightly above GSe and the company's earlier guidance of 15%-18% yoy; yet adj. OP declined by 5% yoy and was 9% below GSe, implying 4.2pp a ...

Core Insights - Deckers Outdoor Corporation (DECK) reported strong fourth-quarter fiscal 2025 results, driven by the performance of its HOKA and UGG brands, with earnings per share of $1.00, exceeding expectations [1][3] - The company did not provide guidance for fiscal 2026 due to macroeconomic uncertainties, leading to a 15.3% decline in shares during after-market trading [1][15] Financial Performance - Net sales increased by 6.5% year over year to $1,021.8 million, surpassing the consensus estimate of $993 million [3] - Gross profit rose 7.5% year over year to $579.8 million, with a gross margin of 56.7%, up from 56.2% in the prior year [4] - Operating income was $173.9 million, a 20.6% increase from the previous year, with an operating margin of 17% [6] Brand Performance - HOKA brand sales grew by 10% year over year to $586.1 million, while UGG brand sales increased by 3.6% to $374.3 million, exceeding estimates [7] - Other brands, including Teva, AHNU, and Koolaburra, saw a decline in sales by 6.3% to $61.3 million [7] Sales Channels and Geography - Wholesale net sales increased by 12.3% year over year to $611.6 million, while DTC net sales decreased by 1.2% to $410.2 million [8] - Domestic net sales remained flat at $647.7 million, whereas international net sales rose by 19.9% to $374.1 million [8] Financial Position - As of March 31, 2025, cash and cash equivalents were $1.89 billion, with total stockholders' equity at $2.51 billion and no outstanding borrowings [9] - The company repurchased 1.78 million shares for $266 million in the fourth quarter and 3.80 million shares for $567 million in fiscal 2025 [10] Future Outlook - For Q1 fiscal 2026, DECK expects revenues between $890 million and $910 million, with HOKA projected to grow in the low-double digits and UGG in the mid-single digits [13] - Gross margin is anticipated to decline by 250 basis points due to higher freight costs and increased promotional activity [13] - SG&A expenses are expected to rise slightly faster than revenues, reflecting continued investments in brand marketing [14]

Core Insights - Canada Goose Holdings Inc. reported higher earnings and revenues for the fourth quarter of fiscal 2025, driven by strong direct-to-consumer (DTC) growth and successful retail execution [1][3]. Financial Performance - Adjusted quarterly earnings per share reached C$1.12, an increase from C$0.99 in the same quarter last year [3]. - Total revenues increased by 7.4% year-over-year to C$384.6 million, with DTC revenues rising 15.7% to C$314.1 million [3][4]. - Gross profit rose 17.8% to C$274.4 million, resulting in a gross margin of 71.3%, up 620 basis points [5]. Revenue Breakdown - DTC comparable sales increased by 6.8%, while wholesale revenues fell 23.2% to C$31.8 million due to reduced order books in EMEA [4]. - Other revenues decreased by 14.2% to C$38.7 million, primarily due to lower employee sales and Friends & Family events [4]. Expenses and Profitability - Selling, general and administrative (SG&A) expenses increased by 4.5% to C$219.3 million, attributed to strategic investments and higher marketing spend [6]. - Operating profit was C$55.1 million, significantly higher than C$23.1 million from the previous year [6]. Financial Position - As of March 30, 2025, Canada Goose had C$334.4 million in cash, C$408.8 million in net debt, and C$541.2 million in equity [7]. - Inventory decreased by 14% year-over-year to C$384 million, reflecting optimized production levels [7]. Future Outlook - The company did not provide financial guidance for fiscal 2026 due to macroeconomic volatility but remains optimistic about brand strength and financial position [8]. - Canada Goose plans to enhance brand visibility through marketing investments and expand its business through strategic channel development [8].

Core Insights - BranchOut Food Inc. reported record Q1 2025 revenue of $3.2 million, a 118% year-over-year increase, marking a significant operational milestone with the full operation of its Peru facility [2][12][16] - The company is strategically positioned to benefit from U.S. tariffs on Chinese imports, providing a cost advantage over competitors reliant on Chinese sourcing [9][10] Financial Performance - Q1 2025 revenue reached $3.2 million, reflecting a 118% increase compared to the previous year [2] - The company anticipates being debt-free by the end of 2025, with substantial improvements in gross margin and cost structure expected to begin in Q2 [6][15] Operational Developments - The Peru facility, which is fully operational, supports over $40 million in annual production capacity and allows for better control over product quality and supply chain efficiency [2][6] - The facility's utilization is expected to improve significantly, with Q2 utilization already up more than 50% compared to Q1 [14] Strategic Partnerships and Market Expansion - BranchOut has expanded its partnership with the largest warehouse club in the U.S., generating nearly $3 million in sales in H1 2025 [3][6] - The company has entered a strategic partnership with MicroDried to lead sales in the industrial ingredient channel, projecting annual revenue of $5–6 million [6][8] Product Innovation and Direct-to-Consumer Strategy - BranchOut is expanding into the direct-to-consumer (DTC) channel, focusing on e-commerce and subscriptions, leveraging its proprietary GentleDry™ technology for competitive advantage [5][10] - The company has launched several innovative products, including Brussels Sprout Crisps and Carrot Sticks, which are now available nationwide [4][7] Market Positioning - With tariffs on Chinese imports at 30%, BranchOut is well-positioned to disrupt the freeze-dried snack market, competing against brands that heavily rely on Chinese sourcing [9][10] - The company is actively discussing replacing China-sourced private label SKUs with its own offerings to provide pricing stability and supply chain resilience [11]

Steven Madden, Ltd. (SHOO) reported first-quarter 2025 results, wherein the top line lagged the Zacks Consensus Estimate, while the bottom line surpassed the same. Total revenues increased and earnings decreased from the year-ago period.SHOO’s first-quarter results were driven by strong execution of strategic initiatives despite challenges from new tariffs on U.S. imports. Focused on adapting to market changes, the company aims to mitigate near-term impacts while positioning for long-term growth. The recent ...

BRC (BRCC) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Matt McGinley - VP - IRChris Mondzelewski - CEOStephen Kadenacy - CFOSarang Vora - Equity ResearchMartin Mitela - Senior Equity Research AssociateDaniel Biolsi - Managing Director Conference Call Participants Michael Baker - Managing Director, Senior Research AnalystNone - AnalystGeorge Kelly - Managing Director, Senior Research Analyst Operator Welcome to Black Rifle Coffee Company First Quarter twenty twenty five Earnings Confe ...

Financial Data and Key Metrics Changes - In Q1 2025, Tarsus Pharmaceuticals generated over $78 million in Xtendi sales, a year-over-year increase of 217%, driven by approximately 72,000 bottles dispensed to patients [4][20] - The gross to net discount was approximately 47%, reflecting strong coverage and an adjustment to Medicare accrual estimates [20][21] - Total operating expenses were approximately $104.6 million, an increase of $14 million compared to Q4 2024, primarily due to direct-to-consumer advertising and related marketing costs [21][22] - The company ended the quarter with approximately $407.9 million in cash and cash equivalents, bolstered by a recent equity raise of approximately $135 million [23] Business Line Data and Key Metrics Changes - Xtendi's sales growth was driven by an expanded sales force and increased prescribing frequency among eye care professionals (ECPs), with a 110% increase in ECPs writing more than one prescription per week compared to Q3 2024 [13][14] - The company anticipates dispensing between 85,000 to 90,000 bottles in Q2 2025, with a gross to net discount expected in the range of 45% to 47% [25] Market Data and Key Metrics Changes - The company reported that over 90% of commercial and Medicare lives are covered, significantly reducing barriers to physician adoption [15][20] - The DTC campaign has led to a 140% increase in average weekly website visits in March 2025 compared to December 2024 [15][18] Company Strategy and Development Direction - Tarsus aims to establish itself as a leader in eye care by creating new categories of treatment, with a focus on Xtendi and the upcoming Xembi launch [4][11] - The company is exploring global opportunities for Xtendi, particularly in Japan and Europe, with potential regulatory approval in Europe expected by 2027 [7][8] - Tarsus is also advancing its pipeline with TPO4 for ocular rosacea, targeting a significant and underserved market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Xtendi, citing strong sales force performance and effective DTC campaigns as key drivers [19][26] - The company anticipates continued revenue growth, despite potential headwinds in Q3 due to seasonal factors, with stronger growth expected in Q4 [25][26] Other Important Information - The company has a proven blueprint for success and is well-positioned for sustained revenue growth in the coming years [11][26] - Management highlighted the importance of patient education and awareness as critical components of their growth strategy [78] Q&A Session Summary Question: Have there been any disruptions in meeting with the FDA regarding pipeline products? - Management confirmed there have been no delays in meeting schedules and they are on track to start trials in the second half of the year [30][31] Question: What is the current split between Medicare and commercial prescriptions? - The script volume is currently split relatively equally between Medicare and commercial prescriptions, with Medicare coverage acting as a significant growth driver [33][34] Question: What are the key drivers for repeat prescribing? - Key drivers include an expanded sales force and improved coverage, which have led to increased frequency of prescribing among doctors [38][40] Question: How is the feedback from the ORION Registry and MGD data being received? - Doctors are responding positively to the new data, which is prompting them to diagnose more patients and consider a broader range of conditions [54] Question: What are the potential factors affecting future guidance? - Factors include the impact of the DTC campaign and macroeconomic events, which may affect visibility for long-range guidance [63] Question: What is the expected level of stocking in the channel? - The company does not anticipate changes in stocking levels, which have remained consistent at around two to two and a half weeks [66]